TARRYTOWN, N.Y., Sept. 17, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed results from the Phase 3 VIVID and VISTA trials of EYLEA® (aflibercept) Injection in Diabetic Macular Edema (DME) will be presented at an oral session during......
More...
